Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Inyta

- PMLiVE

Unruffled by ‘outlier’ claims, Vertex CEO upbeat on Orkambi breakthrough

NHS England going public with price makes deal impossible, says Leiden

- PMLiVE

Vertex chief Jeffrey Leiden to weigh in on Orkambi inquiry

Will be joined by chief commercial officer Stuart Arbuckle

Biomarin

NICE knocks back BioMarin’s Batten disease drug

£500,000 list price too high without long-term data, says watchdog

Eli Lilly HQ

Lilly, Pfizer say NGF drug works in back pain too

Tanezumab was able to show a statistically significant improvement in pain

- PMLiVE

‘Inflexible’ NICE blocking access to rare disease drugs

Spinraza most high profile example of access problem

- PMLiVE

Biosimilar Herceptin helps Roche gain new Perjeta recommendation

NICE decision puts NHS in vanguard for new use

- PMLiVE

Novartis first to benefit from NICE advice on ‘patient preference’

Consultancy spin-off looking to expand services

- PMLiVE

Industry concerned about ‘rushed’ Brexit withdrawal legislation

The Patents Amendment could weaken the UK’s IP framework, warns biopharma

- PMLiVE

NICE and Canadian counterpart to offer joint advice service

Agencies offer parallel scientific advice

- PMLiVE

Pfizer closes on EU approval of lung cancer drug Vizimpro

And AZ claims first with Forxiga in T1 diabetes

- PMLiVE

CAR-Ts go head-to-head after NICE clears Kymriah in DLBCL

Novartis agrees pricing deal with NHS England

- PMLiVE

How to pay for very high cost, curative drugs? ICER and NICE put their heads together

Three HTA bodies seek answers to future value models

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links